{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:49:07Z","timestamp":1773773347968,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,11,21]],"date-time":"2012-11-21T00:00:00Z","timestamp":1353456000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s13277-012-0591-0","type":"journal-article","created":{"date-parts":[[2012,11,22]],"date-time":"2012-11-22T18:07:33Z","timestamp":1353607653000},"page":"643-648","source":"Crossref","is-referenced-by-count":19,"title":["Increased serum level of thymidine kinase 1 correlates with metastatic site in patients with malignant melanoma"],"prefix":"10.1007","volume":"34","author":[{"given":"Bao-Jin","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong-Wen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,11,21]]},"reference":[{"key":"591_CR1","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/01.sla.0000090446.63327.40","volume":"238","author":"MF Kalady","year":"2003","unstructured":"Kalady MF, White RR, Johnson JL, Tyler DS, Seigler HF. Thin melanomas: predictive lethal characteristics from a 30-year clinical experience. Ann Surg. 2003;238:528\u201335. doi: 10.1097\/01.sla.0000090446.63327.40 .","journal-title":"Ann Surg"},{"key":"591_CR2","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1200\/JCO.2006.08.1463","volume":"25","author":"PA Gimotty","year":"2007","unstructured":"Gimotty PA, Elder DE, Fraker DL, Botbyl J, Sellers K, Elenitsas R, Ming ME, Schuchter L, Spitz FR, Czerniecki BJ, Guerry D. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol. 2007;25:1129\u201334. doi: 10.1200\/JCO.2006.08.1463 .","journal-title":"J Clin Oncol"},{"key":"591_CR3","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/jnci\/djp038","volume":"101","author":"BE Gould Rothberg","year":"2009","unstructured":"Gould Rothberg BE, Bracken MB, Rimm DL. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2009;101:452\u201374. doi: 10.1093\/jnci\/djp038 .","journal-title":"J Natl Cancer Inst"},{"key":"591_CR4","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/jnci\/djj103","volume":"98","author":"V Winnepenninckx","year":"2006","unstructured":"Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Melanoma Group of the European Organization for Research and Treatment of Cancer. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst. 2006;98:472\u201382. doi: 10.1093\/jnci\/djj103 .","journal-title":"J Natl Cancer Inst"},{"key":"591_CR5","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jaad.2008.07.020","volume":"59","author":"SR Florell","year":"2008","unstructured":"Florell SR, Smoller BR, Boucher KM, Grossman D, Harris RM, Bowen GM, Leachman SA. Sampling of melanocytic nevi for research purposes: a prospective, pilot study to determine effect on diagnosis. J Am Acad Dermatol. 2008;59:814\u201321.","journal-title":"J Am Acad Dermatol"},{"key":"591_CR6","doi-asserted-by":"crossref","first-page":"10652","DOI":"10.1158\/0008-5472.CAN-06-0921","volume":"66","author":"D Becker","year":"2006","unstructured":"Becker D, Mihm MC, Hewitt SM, Sondak VK, Fountain JW, Thurin M. Markers and tissue resources for melanoma: meeting report. Cancer Res. 2006;66:10652\u20137. doi: 10.1158\/0008-5472.CAN-06-0921 .","journal-title":"Cancer Res"},{"key":"591_CR7","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1128\/MCB.24.2.514-526.2004","volume":"24","author":"PY Ke","year":"2004","unstructured":"Ke PY, Chang ZF. Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex\/cyclosome-CDH1-mediated pathway. Mol Cell Biol. 2004;24:514\u201326. doi: 10.1128\/MCB.24.2.514-526.2004 .","journal-title":"Mol Cell Biol"},{"key":"591_CR8","first-page":"341","volume":"4","author":"AS Al-Madhoun","year":"2004","unstructured":"Al-Madhoun AS, Tjarks W, Eriksson S. The role of thymidine kinases in the activation of pyrimidine nucleoside analogues. Mini Rev Med Chem. 2004;4:341\u201350.","journal-title":"Mini Rev Med Chem."},{"key":"591_CR9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0022-1759(03)00062-0","volume":"277","author":"C Wu","year":"2003","unstructured":"Wu C, Yang R, Zhou J, Bao S, Zou L, Zhang P, Mao Y, Wu J, He Q. Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1. J Immunol Methods. 2003;277:157\u201369.","journal-title":"J Immunol Methods"},{"key":"591_CR10","first-page":"266","volume":"13","author":"A Gowda","year":"2006","unstructured":"Gowda A, Byrd JC. Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemia. Curr Opin Hematol. 2006;13:266\u201372.","journal-title":"Curr Opin Hematol"},{"key":"591_CR11","first-page":"595","volume":"18","author":"BR Madewell","year":"2004","unstructured":"Madewell BR. Serum thymidine kinase activity: an alternative to histologic markers of cellular proliferation in canine lymphoma. J Vet Intern Med. 2004;18:595\u20136.","journal-title":"J Vet Intern Med."},{"key":"591_CR12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1023\/A:1011138825593","volume":"12","author":"F Raimondo Di","year":"2001","unstructured":"Di Raimondo F, Giustolisi R, Lerner S, Cacciola E, O\u2019Brien S, Kantarjian H, Keating MJ. Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. Ann Oncol. 2001;12:621\u20135.","journal-title":"Ann Oncol"},{"key":"591_CR13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0009-8981(92)90008-E","volume":"206","author":"MK Schwartz","year":"1992","unstructured":"Schwartz MK. Enzymes as prognostic markers and therapeutic indicators in patients with cancer. Clin Chim Acta. 1992;206:77\u201382.","journal-title":"Clin Chim Acta."},{"key":"591_CR14","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/sj.leu.2404536","volume":"21","author":"KL O\u2019Neill","year":"2007","unstructured":"O\u2019Neill KL, Zhang F, Li H, Fuja DG, Murray BK. Thymidine kinase 1\u2014a prognostic and diagnostic indicator in ALL and AML patients. Leukemia. 2007;21:560\u20133. doi: 10.1038\/sj.leu.2404536 .","journal-title":"Leukemia"},{"key":"591_CR15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3727\/096504006776613965","volume":"15","author":"J Zhang","year":"2006","unstructured":"Zhang J, Jia Q, Zou S, Zhang P, Zhang X, Skog S, Luo P, Zhang W, He Q. Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. Oncol Rep. 2006;15:455\u201361.","journal-title":"Oncol Rep."},{"key":"591_CR16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000055352","volume":"61","author":"R Fujiwaki","year":"2001","unstructured":"Fujiwaki R, Hata K, Moriyama M, Iwanari O, Katabuchi H, Okamura H, Miyazaki K. Clinical value of thymidine kinase in patients with cervical carcinoma. Oncology. 2001;61:47\u201354.","journal-title":"Oncology"},{"key":"591_CR17","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2001.19.16.3635","volume":"19","author":"CM Balch","year":"2001","unstructured":"Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton Jr A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635\u201348.","journal-title":"J Clin Oncol"},{"key":"591_CR18","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3892\/etm.2011.338","volume":"2","author":"Y Liu","year":"2011","unstructured":"Liu Y, Ling Y, Qi Q, Tang Y, Xu J, Tong Z, Sheng G, Yang Q, Pan Y. Changes in serum thymidine kinase 1 levels during chemotherapy correlate with objective response in patients with advanced gastric cancer. Exp Ther Med. 2011;2:1177\u201381. doi: 10.3892\/etm.2011.338 .","journal-title":"Exp Ther Med."},{"key":"591_CR19","first-page":"753","volume":"2","author":"DC Lev","year":"2003","unstructured":"Lev DC, Ruiz M, Mills L, McGary EC, Price JE, Bar-Eli M. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther. 2003;2:753\u201363.","journal-title":"Mol Cancer Ther"},{"key":"591_CR20","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00281-011-0247-y","volume":"33","author":"MT Krauze","year":"2011","unstructured":"Krauze MT, Tarhini A, Gogas H, Kirkwood JM. Prognostic significance of autoimmunity during treatment of melanoma with interferon. Semin Immunopathol. 2011;33:385\u201391.","journal-title":"Semin Immunopathol"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-012-0591-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-012-0591-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-012-0591-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T22:59:09Z","timestamp":1643669949000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-012-0591-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,21]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["591"],"URL":"https:\/\/doi.org\/10.1007\/s13277-012-0591-0","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,21]]}}}